CCO Oncology Podcast
by Clinical Care OptionsUpdates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
Copyright: 2020 CCO Oncology Podcast
Episodes
Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer
25m · PublishedIn this episode, Manali Bhave, MD; Annalise Labatut, PharmD, BCOP; and nurse practitioner Jamie L. Carroll, CNP, APRN, MSN, begin by discussing the landmark EMERALD study that led to FDA approval of elacestrant, the first oral selective estrogen receptor degrader (SERD) for treatment of hormone receptor–positive/HER2-negative metastatic breast cancer. Dr. Bhave also briefly reviews ongoing clinical trials of other oral SERDs for estrogen receptor–positive/HER2-negative metastatic breast cancer.
Next, the panel discusses the possible adverse effects with elacestrant, potential drug–drug interactions, and their personal experiences with managing adverse effects in their patients.
Finally, the discussion turns to methods for promoting treatment adherence and persistence and briefly touches on insurance coverage and affordability, including ways that patients and providers can work together to ensure access to approved oral SERDs.
Presenters:
Manali Bhave, MD
Phase I Medical Director
Assistant Professor
Department of Hematology & Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia
Annalise Labatut, PharmD, BCOP
Oncology Clinical Pharmacy Specialist – Breast Oncology
Emory Healthcare/Winship Cancer Institute
Atlanta, Georgia
Jamie L. Carroll, CNP, APRN, MSN
Assistant Professor of Medical Oncology
Mayo Clinic
Rochester, Minnesota
Link to the full program:
https://bit.ly/3UT5Be8
Claim CME Credit:
https://bit.ly/4dBuxhx
Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
47m · PublishedIn this episode,Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the NCCN CLL guidelines and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes. The greater discussion addresses:
- Optimal selection of therapy for treatment-naive CLL, including second-generation covalent BTK inhibitors
- Considerations in therapy selection for previously treated CLL
- Novel strategies for treating CLL
Presenters:
Danielle M. Brander, MD
Assistant Professor of Medicine
Division of Hematologic Malignancies and Cellular Therapy
Duke Cancer Institute
Durham, North Carolina
Brian Hill, MD, PhD
Director, Lymphoid Malignancies Program
Staff Physician, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio
Deborah Stephens, DO
Associate Professor
Director of the CLL Program
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, North Carolina
Content based on a live and online CME program supported by educational grants from AstraZeneca; BeiGene, Ltd.; and Lilly.
Link to full program including downloadable slides:
https://bit.ly/49YxtSq
Homologous Recombination Repair (HRR) Testing and Targeted Therapy in Prostate Cancer
48m · PublishedIn this episode, Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, discuss optimal biomarker testing to guide treatment decisions in advanced prostate cancer, with topics including:
- Rationale for targeting PARP in prostate cancer with ARI combinations
- Study design nuances and findings from key randomized phase III clinical trials evaluating combination therapy with a PARP inhibitor and ARI, including PROpel, MAGNITUDE, and TALAPRO-2
- FDA approvals of combination therapy with a PARP inhibitor and ARI, including a comparison of populations based on mutations
- Optimal biomarker testing for gene mutations in homologous recombination and mismatch repair pathways
- Tips for optimal coordination between pathology and medical oncology
Presenters:
Heather H. Cheng, MD, PhD
Associate Professor
Department of Medicine
Division of Hematology and Oncology
Attending Physician
Department of Genitourinary Medical Oncology
Fred Hutchinson Cancer Center
Seattle, Washington
Colin C. Pritchard, MD, PhD
Co-Director
Genetics and Solid Tumors Laboratory
University of Washington Medical Center
Professor
Department of Laboratory Medicine and Pathology
University of Washington
Seattle, Washington
Content based on an online CME program supported by an independent educational grant from Pfizer, Inc.
Link to full program:
https://bit.ly/3PFagxb
Real-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast Cancer
36m · PublishedIn this podcast episode, Sara M. Tolaney, MD, MPH, and Melinda Telli, MD, delve into the critical aspects of the current therapeutic landscape for patients withunresectable or metastatic HER2-low, hormone receptor–positive, and triple-negative breast cancer, including:
- Challenges with thepathologic testing for HER2-low expression
- Optimal treatment of patients with HER2-low advanced breast cancer
- Role of TROP-2–targeted therapies
- Management of ADC-associated adverse events to optimize treatment outcomes
- ADCs on the horizon for patients with advanced breast cancer
Presenters:
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Melinda Telli, MD
Professor of Medicine
Stanford University School of Medicine
Director, Breast Cancer Program
Stanford Cancer Institute
Palo Alto, California
Content based on an online CME program supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Link to full program:
https://bit.ly/49WxRBM
Current Considerations for Adverse Event Management With HER3-Directed Agents
12m · PublishedThe third and final episode in a 3-part series covers the safety profile of and considerations for managing adverse events associated with HER3-targeted antibody–drug conjugates, including patritumab deruxtecan (HER3-DXd) and others, in the setting of lung cancer.
Presenters in this series include:
Rebecca S. Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts
Helena Yu, MD
Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Supported by an educational grant from Daiichi Sankyo, Inc.
Link to full program, including a downloadable highlights slideset:
https://bit.ly/48ecElW
Unpacking the Potential of HER3-Targeted Therapy in NSCLC
15m · PublishedThis second episode in a 3-part series on HER3-targeted agents in NSCLC covers current clinical trials with HER3-targeted therapy, including:
- Recent data on patritumab deruxtecan (HER3-DXd) in the HERTHENA-Lung01 trial
- The EGFRxHER3 bispecific antibodies BL-B01D1 and izalontamab
- The HER2xHER3 bispecific antibody zenocutuzumab
- The HER3-targeted antibody–drug conjugate SHR-A2009
Presenters in this series include:
Rebecca S. Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts
Helena Yu, MD
Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Supported by an educational grant from Daiichi Sankyo, Inc.
Link to full program, including a downloadable highlights slideset:
https://bit.ly/48ecElW
Recent Advances in ADCs and Rationale for HER3 as a Target in Lung Cancer
8m · PublishedThis first episode in a 3-part series tackles the role of HER3 in cancer, specifically in NSCLC, and how HER3 can be effectively targeted with ADCs.
Presenters in this series include:
Rebecca S. Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts
Helena Yu, MD
Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Supported by an educational grant from Daiichi Sankyo, Inc.
Link to full program, including a downloadable highlights slideset:
https://bit.ly/48ecElW
Expert Insight on Seminal New Clinical Trial Data Presented at the 2023 IGCS Conference Informing Treatment for Endometrial, Ovarian, and Cervical Cancers
30m · PublishedIn this episode, Brian Slomovitz, MD, MS, FACOG, and Keiichi Fujiwara, MD, PhD, share their thoughts and opinions on seminal data presented at the 2023 IGCS annual meeting for endometrial, ovarian, and cervical cancers, including:
- Phase III NRG GY018 trial of carboplatin and paclitaxel with or without pembrolizumab followed by pembrolizumab or placebo maintenance for 2 years in patients with measurable stage III/IVA, stage IVB, or recurrent endometrial cancer.
- Phase III ENGOT-EN6/GOG-3031/RUBY trial of carboplatin and paclitaxel with or without dostarlimab followed by dostarlimab or placebo maintenance for 3 years in patients with primary advanced or recurrent endometrial cancer.
- Results from the double-blind, randomized, placebo-controlled phase III AtTEnd trial of atezolizumab plus carboplatin/paclitaxel in advanced or recurrent endometrial cancer.
- Randomized, multicenter, double-blind, placebo-controlled phase III DUO-E study of carboplatin and paclitaxel vs durvalumab plus carboplatin and paclitaxel followed by durvalumab maintenance with or without olaparib as frontline treatment of newly diagnosed, advanced, endometrial cancer.
- An international, randomized, multicenter phase III trial evaluating short-course chemotherapy followed by chemoradiation vs chemoradiation alone in patients with newly diagnosed stage IB1N+, IB2, II, IIIB, IVA squamous, adeno, adenosquamous cervical cancer (INTERLACE).
- Randomized, double-blind, placebo-controlled phase III KEYNOTE-A18 trial of pembrolizumab plus concurrent chemoradiotherapy vs placebo plus chemoradiation in patients with high-risk locally advanced cervical cancer.
- Phase III ICON8B study comparing carboplatin, paclitaxel, and bevacizumab every 3 weeks vs dose-dense weekly paclitaxel plus bevacizumab every 3 weeks in newly diagnosed high-risk epithelial ovarian cancer, either stage III (with residual disease or requiring new adjuvant chemotherapy) or stage IV.
Presenters:
Brian Slomovitz, MD, MS, FACOG
Director
Gynecologic Oncology
Mount Sinai Medical Center
Professor
Obsterics and Gynecology
Florida International University
Member, Board of Directors
GOG Foundation
Uterine Cancer Lead
GOG Partners
Miami, Florida
Keiichi Fujiwara, MD, PhD
Professor of Gynecologic Oncology
Saitama Medical University International Medical Center
Hidaka, Japan
Professor of OBGYN
International University of Health and Welfare
Narita, Japan
This educational activity is supported by educational grants from AstraZeneca, Genmab, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure, and Seagen.
Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:
https://bit.ly/424E3Uq
Novel Emerging Investigational Treatment Strategies for Patients With Myelofibrosis
19m · PublishedIn this episode, Jacqueline S. Garcia, MD, discusses novel agents and strategies in clinical trial development for treating patients with myelofibrosis, including:
- Navitoclax (BCL-XL/BCL-2 inhibitor)
- Pelabresib (BET inhibitor)
- Imetelstat (telomerase inhibitor)
- Luspatercept (erythroid maturation agent)
- Additional strategies
Presenter:
Jacqueline S. Garcia, MD
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
Link to the full program here. https://bit.ly/47z8WCV
A Year in Review and a Look to the Future: BTKi in CLL and MCL
27m · PublishedIn this episode, Ana Marin-Niebla, MD, PhD, and Stephan Stilgenbauer, MD, discuss key trial data on the use of BTK inhibitors in CLL and MCL throughout the past year, how these studies have impacted their practice, and what data they are looking forward to in the near future. The discussion includes analyses of:
- SHINE: First-Line Ibrutinib + Bendamustine/Rituximab Followed by Rituximab Maintenance in Older Patients With MCL
- TRIANGLE: Ibrutinib + Chemoimmunotherapy With or Without ASCT vs Chemoimmunotherapy Followed by ASCT in Younger Patients with Previously Untreated MCL
- ZUMA-2: Brexucabtagene Autoleucel in R/R MCL
- BRUIN: Pirtobrutinib for Previously Treated MCL
- GLOW: Fixed-Duration Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab in Previously Untreated CLL
- FLAIR: Ibrutinib + Venetoclax vs FCR in Previously Untreated CLL
- ELEVATE-RR: Acalabrutinib vs Ibrutinib in Previously Treated CLL
- ALPINE: Zanubrutinib vs Ibrutinib in Previously Treated CLL
- BRUIN: Pirtobrutinib for Previously Treated CLL
Presenters:
Ana Marin-Niebla, MD, PhD
Hematology Consultant, Lymphoma Unit
Vall d’Hebron Institute of Oncology, Hematology Department
Hospital Universitario Vall d’Hebron
Barcelona, Spain
Stephan Stilgenbauer, MD
Medical Director Comprehensive Cancer Center Ulm
Head, Early Clinical Trials Unit
Head, Division of CLL Dept. of Internal Medicine III
University Medical Center
Ulm University
Ulm, Germany
Link to full program:
https://bit.ly/3MNaUri
CCO Oncology Podcast has 170 episodes in total of non- explicit content. Total playtime is 63:34:40. The language of the podcast is English. This podcast has been added on November 22nd 2022. It might contain more episodes than the ones shown here. It was last updated on May 28th, 2024 12:10.